玻璃体腔内注射Bevacizumab治疗视网膜新生血管性眼压改变  

Short-term intraocular pressure Changes immediately After Intravitreal Injections of bevacizumab for retinal neovasularization disease

作　　者：韩国鸽[1] 陈长征[1] 邢怡桥[1] 刘增平[1] 许菲[1] 王君怡[1] 王晶[1] 

机构地区：[1]武汉大学人民医院眼科,武汉大学医学院眼科研究所,湖北省武汉市430060

出　　处：《中国实用眼科杂志》2009年第9期1009-1011,共3页Chinese Journal of Practical Ophthalmology

基　　金：湖北省重大项目重大眼部疾病预防与临床控制技术研究;湖北省科技攻关项目眼部疾病防治技术研究（2006AA301B58）

摘　　要：目的初步探讨玻璃体腔内注射Bevacizumab治疗视网膜新生血管性疾病术后早期眼压变化。方法对13例（18眼）视网膜新生血管性疾病，其中年龄相关性黄斑变性（10例，12眼）、糖尿病视网膜病变（3例，6眼），所有患者分别在第0周，6周，12周行玻璃体腔内注射Bevacizumab1．25mg。在注射前后5min，30min，1h，2h进行眼压检查。结果以0周注射为例，5min，30min，1h，2h内眼压分别为（18．7±5．4）mmHg、（18．1±5．3）mmHg、（17．3±5．4）mmHg，与注射前平均眼压（14．6±4．1）mmHg相比差异有统计学意义（t值分别为2．81、3．45、2．63，P值均〈0．05）。而随访的2h平均眼压降为（15．6±5．8）mmHg，与注射前相比差异无统计学意义（t=-0．15，19〉0．5）。在总共48次注射中，注射后眼压监测5min时IOP值高于正常眼压值（IOP〉21mmHg）的百分率为41．7％，30min时高于正常眼压值的百分率为22．9％，而在1h内85．4％，2h内91．7％的眼压测量值恢复正常。结论玻璃体腔内注射Bevacizumab治疗视网膜新生血管性疾病早期眼压（5min）呈现短暂升高后下降，术后2h可作为门诊玻璃体腔内注射Bevacizumab早期眼压监测时间点。Objective To assess short-term trends and the need to monitor intraocular pressure （lOP） changes immediately after intraocular injection of bevacizumab for retinal neovasularization disease.Methods A total of 18 eyes of 13 consecutive patients including 10 cases of neovasular aged-related macular degenera- tion （ 12 eyes）, 3 cases of diabetic retinopathy （6 eyes） diseases received a single bevacizumab intravitreal injection of 1.25mg at 0th week, 6th week and 12th week.Intraocular pressures were measured before injection, immediately after injection at the time of 5min, 30min, l h and 2h.Results Take 0 week as an example, the mean intraocular pressure was increased remarkably at the follow-up time of 5 min, 30min, lh, [（ 18.7±5.4） mm Hg, （18.1±5.3） mmHg, （17.3±5.4） mmHg] compared with those before injection [（14.6±4.1） mmHg, t values were 2.81, 3.45, 2.63 respectively, P 〈0.05].However, the mean intraocular pressure at 2h （15.6±5.8） mmHg shows no significant difference comparing with the value before injection （t=0.15, P〉0.5）.During a total of 48 injections, 41.7% lOP value at 5min is higher than the normal value （ IOP〉21mmHg）, and the percentage decreased to 22.9% at 30min.Nevertheless, 85.4%, 91.7% of IOP value returns back to normal at lh, 2h respectively.Conclusions Elevations in lOP immediately （5min） after intravitreal injections are common, but are transient during the treatment of intravitreal injections ofbevacizumab for retinal neovasularization disease which indicates that 2h could be taken as the monitoring short term IOP time point for the out-patients.

关 键 词：BEVACIZUMAB 视网膜新生血管 玻璃体腔内注射 眼压 

分 类 号：R979.1[医药卫生—药品] R774.1[医药卫生—药学]